Topic collections

GUIDELINES
Management of atopic eczema in children aged up to 12 years: summary of NICE guidance Sue Lewis-Jones, 1 Moira A Mugglestone, 2 on behalf of the Guideline Development Group
Why read this summary? Atopic eczema affects one in five children in the United Kingdom 1 and accounts for 1 in 30 consultations in community care.
2 Recent data suggest that impaired skin barrier function is a major causative factor. 3 4 There may be considerable physical and emotional morbidity for the child and the parents or carers, particularly if the disease is poorly controlled. 5 Yet most healthcare professionals receive little or no relevant training in dermatology, 6 and lack of knowledge, confusion, and anxiety about many of the available treatments are widespread among parents. 5 7 This article summarises the most recent guidance from the National Institute for Health and Clinical Excellence (NICE) on how to manage atopic eczema in children from birth up to the age of 12 years. 8 Recommendations NICE recommendations are based on systematic reviews of the best available evidence. When minimal evidence is available, a range of consensus techniques is used to develop recommendations. In this summary, recommendations derived primarily from consensus techniques are indicated with an asterisk (*).
Diagnosis and assessment
Diagnose atopic eczema in children according to the criteria in box 1. Adopt a holistic approach to assessing a child's atopic eczema*, taking account of the physical severity of the eczema (box 2) and its impact on quality of life (which may range from no impact to severe limitation of everyday activities and 
Overcoming barriers
If used correctly, the structured approach recommended in this guidance should allow improved quality of care and more cost effective clinical management of atopic eczema. The approach requires an initial investment in time to assess the child's atopic eczema adequately and discuss parental anxieties about treatments, emphasising that the benefits of topical corticosteroids outweigh possible harms. Written care plans should cover treatment of flares and episodes of infected eczema to educate parents on when topical corticosteroids (and other treatments) are appropriate. This investment should, however, lead to longer term benefits, empowering children with atopic eczema and their parents or carers to take control of management, and potentially reducing the need for frequent monitoring and thus the workload of healthcare professionals.
To support implementation, NICE and the guideline development group have developed a version of the guidance (available from December 2007 at www.nice. org.uk/CG057PublicInfoEnglish) that can be given to children with atopic eczema and their parents or carers).
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Box 4 Stepped approach to management of atopic eczema
Tailor treatment to severity
Step 
